학술논문
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFRT790M-Mutated NSCLC: A Phase 2b Study
Document Type
Article
Author
Shi, Yuankai; Wu, Shiman; Wang, Ke; Cang, Shundong; Yao, Wenxiu; Fan, Yun; Wu, Lin; Huang, Meijuan; Li, Xingya; Pan, Yueyin; Yang, Zhixiong; Zhu, Bo; Chen, Gongyan; Shi, Jianhua; Sun, Meili; Fang, Jian; Wang, Lijun; Chen, Zhaohong; Liu, Chunling; Li, Jingzhang; Liu, Jiwei; Sun, Shenghua; Zhao, Yanqiu; Guo, Yanzhen; Meng, Zili; Liu, Zhefeng; Han, Zhigang; Lu, Hong; Ma, Rui; Hu, Sheng; Zhao, Guofang; Liu, Zheng; Xie, Congying; Zhong, Diansheng; Zhao, Hui; Yu, Huiqing; Zhang, Longzhen; Bi, Minghong; Yi, Shanyong; Guo, Shuliang; Yi, Tienan; Li, Wen; Lin, Yingcheng; Shu, Yongqian; Chen, Zhendong; Guo, Zhongliang; Greco, Michael; Wang, Tingting; Shen, Haijiao
Source
Journal of Thoracic Oncology; November 2022, Vol. 17 Issue: 11 p1306-1317, 12p
Subject
Language
ISSN
15560864; 15561380
Abstract
Rezivertinib (BPI-7711) is a novel third-generation EGFRtyrosine kinase inhibitor (TKI) targeting both EGFR-sensitizing mutations and EGFRT790M mutation. This study aimed to evaluate the efficacy and safety of rezivertinib in patients with locally advanced or metastatic/recurrent EGFRT790M-mutated NSCLC.